Rigamonti Nicoletta, Sebellin Jessica, Pipitone Francesca, Realdon Nicola, Carpanese Debora, Coppola Marina
Pharmacy Unit, Veneto Institute of Oncology (IOV), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Comprehensive Cancer Centre, 35128 Padua, Italy.
Pharmaceutical and Pharmacological Sciences Department, University of Padua, 35122 Padua, Italy.
Pharmaceutics. 2023 May 7;15(5):1429. doi: 10.3390/pharmaceutics15051429.
Preparation of injectable anticancer drugs in hospital pharmacies is a high-risk activity that requires a proper risk assessment (RA) and quality assurance system (QAS) to ensure both a decrease in risk associated with chemotherapy compounding and high quality of the final product, especially in terms of its microbiological stability.
At the centralized compounding unit (UFA) of the Italian Hospital IOV-IRCCS, a quick and deductive method was applied to evaluate the "added value" provided by each prescribed preparation, and its RA was calculated applying a formula that integrates different pharmacological, technological and organizational aspects. According to specific RA range values, the preparations were divided into different risk levels, in order to determine the QAS to be adopted, according to the Italian Ministry of Health guidelines, whose adherence was meticulously evaluated through a specific self-assessment procedure. A review of the scientific literature was carried out to integrate the risk-based predictive extended stability (RBPES) of drugs with data concerning their physiochemical and biological stability.
Based on the self-assessment comprising all microbiological validations of the working area, personnel and products, the microbiological risk level within the IOV-IRCCS' UFA was defined through the creation of a transcoding matrix, conferring a microbiological stability to preparations and vial leftovers of a maximum of 7 days. The calculated RBPES were successfully integrated with stability data from the literature, leading to the drafting of a stability table of drugs and preparations in use in our UFA.
Our methods allowed us to perform an in-depth analysis of the highly specific and technical process of anticancer drug compounding in our UFA, ensuring a certain grade of quality and safety to preparations, especially in terms of microbiological stability. The resulting RBPES table represents an invaluable tool with positive repercussions at organizational and economic levels.
医院药房配制注射用抗癌药物是一项高风险活动,需要适当的风险评估(RA)和质量保证体系(QAS),以确保降低化疗配药相关风险并保证最终产品的高质量,尤其是在微生物稳定性方面。
在意大利IOV - IRCCS医院的集中配药单元(UFA),应用一种快速演绎法评估每种处方制剂的“附加值”,并使用一个整合了不同药理学、技术和组织方面因素的公式计算其风险评估值。根据特定的风险评估范围值,将制剂分为不同风险等级,以便根据意大利卫生部指南确定应采用的质量保证体系,并通过特定的自我评估程序严格评估对该指南的遵守情况。开展了一项科学文献综述,将药物基于风险的预测性延长稳定性(RBPES)与有关其理化和生物稳定性的数据相结合。
基于涵盖工作区域、人员和产品所有微生物验证的自我评估,通过创建一个转码矩阵确定了IOV - IRCCS医院UFA内的微生物风险水平,赋予制剂和小瓶剩余物最多7天的微生物稳定性。计算得出的RBPES与文献中的稳定性数据成功整合,从而制定了我们UFA中使用的药物和制剂稳定性表。
我们的方法使我们能够对UFA中抗癌药物配药这一高度特定和技术性的过程进行深入分析,确保制剂具有一定程度的质量和安全性,尤其是在微生物稳定性方面。由此产生的RBPES表是一个具有重要价值的工具,在组织和经济层面都有积极影响。